Table 2.
Laboratory and radiographic findings of patients with COVID-19 on admission
| Total (n = 150) | Non-survivor (n = 31) | Survivor (n = 119) | P-Value | |
|---|---|---|---|---|
| Laboratory findings | ||||
| Hematologic | ||||
| White blood cell counts, × 109 per L | 5.7 (4.0-8.2) | 9.1 (5.2-12.3) | 5.5 (3.9-7.2) | <0.001 |
| Lymphocyte counts, × 109 per L | 1.1 (0.7-1.6) | 0.6 (0.4-0.8) | 1.3 (0.9-1.7) | <0.001 |
| Neutrophil counts, × 109 per L | 3.8 (2.3-6.2) | 8.5 (4.1-10.9) | 3.5 (2.1-5.2) | <0.001 |
| Hemoglobin, g per L | 124.5 (117.0-136.0) | 128.0 (123.0-136.5) | 123.0 (116.0-136.0) | 0.298 |
| Hematocrit, % | 38.3 (35.6-41.9) | 37.9 (35.6-41.8) | 38.3 (35.6-42.2) | 0.913 |
| Platelet counts, × 109 per L | 191.5 (144.3-250.0) | 121.0 (104.0-193.5) | 198.0 (161.0-257.0) | <0.001 |
| Biochemical | ||||
| Aspartate aminotransferase, U/L | 19.4 (16.0-31.8) | 31.0 (20.5-50.0) | 18.0 (15.0-26.3) | <0.001 |
| Alanine aminotransferase, U/L | 19.0 (13.0-32.0) | 24.0 (19.5-34.0) | 17.0 (12.0-32.0) | 0.044 |
| Total bilirubin, μmol/L | 11.4 (8.3-17.5) | 19.3 (10.3-28.8) | 10.6 (8.1-15.6) | <0.001 |
| Albumin, g/L | 37.8 (34.6-41.7) | 33.3 (29.7-35.5) | 39.1 (35.9-42.2) | <0.001 |
| Globulin, g/L | 27.8 (25.1-30.8) | 30.3 (25.4-34.8) | 27.4 (25.1-29.9) | 0.018 |
| Urea nitrogen, mmol/L | 4.3 (3.2-6.2) | 9.1 (4.6-13.3) | 4.1 (3.1-5.0) | <0.001 |
| Creatinine, μmol/L | 73.5 (57.5-90.1) | 88.7 (72.9-108.0) | 70.2 (54.6-84.0) | 0.001 |
| Fasting blood glucose, mmol/L | 5.8 (5.0-7.0) | 7.8 (5.9-12.9) | 5.8 (4.8-6.4) | <0.001 |
| Lactate dehydrogenase, U/L | 208.5 (178.3-270.8) | 423.0 (208.5-571.0) | 208.5 (168.5-230.0) | <0.001 |
| Coagulation function | ||||
| Prothrombin time, s* | 12 (11.4-12.7) | 12.7 (12.0-13.6) | 11.9 (11.1-12.5) | <0.001 |
| Activated partial thromboplastin time, s* | 31.2 (29.3-33.0) | 31.0 (27.5-34.1) | 31.2 (29.5-32.8) | 0.595 |
| D-dimer, μg/L* | 196.0 (101.3-384.3) | 638.0 (258.5-5189.5) | 173.0 (88.5-264.0) | <0.001 |
| Infection-related indices | ||||
| Erythrocyte sedimentation rate, mm/h† | 29.0 (18.5-43.5) | 29.0 (28.5-44.5) | 29.0 (17.0-41.5) | 0.165 |
| C-Reactive protein, mg/L ‡ | 9.2 (1.0-47.3) | 57.6 (31.5-97.4) | 7 (0.5-30.8) | <0.001 |
| Procalcitonin, ng/mL, n (%)§ | ||||
| <0.5 | 77 (83.7%) | 8 (53.3%) | 69 (89.6%) | |
| 0.5-2 | 10 (10.9%) | 5 (33.3%) | 5 (6.5%) | 0.007 |
| >2 | 5 (5.4%) | 2 (13.3%) | 3 (3.9%) | |
| Imaging features | ||||
| Ground glass opacification, n (%) | 129 (86.0%) | 29 (93.5%) | 100 (84.0%) | 0.043 |
| Pleural effusion, n (%) | 10 (6.7%) | 7 (22.6%) | 3 (2.5%) | <0.001 |
| Unilateral pulmonary infiltration, n (%) | 26 (17.3%) | 1 (3.2%) | 25 (21.0%) | 0.020 |
| Bilateral pulmonary infiltration, n (%) | 124 (82.7%) | 30 (96.8%) | 94 (79.0%) | 0.020 |
*
Data available for 141 patients, missing for 9 survivors.
†
Data available for 111 patients, including 21 non-survivors and 90 survivors.
‡
Data available for 143 patients, including 25 non-survivors and 118 survivors.
§
Data available for 93 patients, including 15 non-survivors and 78 survivors.